The incidence and risk of cutaneous toxicities associated with dabrafenib in melanoma patients: a systematic review and meta-analysis

Chen, Peng; Lei, Jiexin

doi:10.1136/ejhpharm-2020-002347

Cited by 9 publications

(2 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, it should be noted that the hair has a dry, brittle and curly appearance; in addition, patients show characteristic hypertrichosis and trichomegaly [ 13 ]. BRAF inhibitors lead to initial alopecia in ≈20% of patients, although hair regrowth may occur despite continued treatment [ 35 ]. Notably, while the use of trametinib (MEK inhibitor) leads to alopecia in about 13% of cases, dual BRAF/MEK inhibition with vemurafenib/cobimetinib or dabrafenib/trametinib leads to alopecia in 13% and 6% of cases, respectively [ 13 , 14 ].…”

Section: Cancer-related Alopecia: Mechanisms and Epidemiologymentioning

confidence: 99%

Cancer-Related Alopecia: From Etiologies to Global Management

Quesada

Guichard²,

Fiteni

2021

Cancers

View full text Add to dashboard Cite

Alopecia represents a multifaceted challenge with distinct etiologies and consequences. Transposed to the world of oncology, different types of alopecia and molecular pathways have been characterized, allowing a better understanding of the underlying mechanisms. In patients with cancer, alopecia can be iatrogenic (i.e., due to conventional chemotherapies, endocrine therapies, targeted therapies, immunotherapies, radiotherapy and surgery) or a direct consequence of the disease itself (e.g., malnutrition, scalp metastases and paraneoplastic syndromes). Identification of the actual incriminated mechanism(s) is therefore essential in order to deliver appropriate supportive care, whether preventive or curative. On the preventive side, the last few years have seen the advent of the automated cooling cap, a prophylactic approach supported by several randomized clinical trials. On the curative side, although the treatments currently available are limited, several promising therapeutic approaches are under development. Appropriate alopecia management is essential, particularly regarding its psychological repercussions with significant consequences on the quality of life of patients and their family and with a potential impact on treatment compliance.

show abstract

Section: Cancer-related Alopecia: Mechanisms and Epidemiologymentioning

confidence: 99%

Cancer-Related Alopecia: From Etiologies to Global Management

Quesada

Guichard²,

Fiteni

2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Currently, approved melanoma therapy includes surgical excision, radiation therapy, and chemotherapy with dacarbazine, interferons, immune checkpoint therapy (e.g., ipilimumab, nivolumab, pembrolizumab), and targeted therapy (e.g., dabrafenib, vemurafenib, dabrafenib) [ 16 , 17 , 18 ]. Unfortunately, even innovative and combined therapies are associated with selective usage, limited efficacy, adverse events, and the development of resistance [ 19 , 20 , 21 , 22 , 23 ]. Thus, the search for new therapies is still ongoing, which includes, among others, cell therapy, cytokines, and drug repurposing [ 24 , 25 ].…”

Section: Introductionmentioning

confidence: 99%

The Anticancer Potential of Doxycycline and Minocycline—A Comparative Study on Amelanotic Melanoma Cell Lines

Rok

Rzepka

Kowalska

et al. 2022

IJMS

View full text Add to dashboard Cite

Malignant melanoma is still a serious medical problem. Relatively high mortality, a still-growing number of newly diagnosed cases, and insufficiently effective methods of therapy necessitate melanoma research. Tetracyclines are compounds with pleiotropic pharmacological properties. Previously published studies on melanotic melanoma cells ascertained that minocycline and doxycycline exerted an anti-melanoma effect. The purpose of the study was to assess the anti-melanoma potential and mechanisms of action of minocycline and doxycycline using A375 and C32 human amelanotic melanoma cell lines. The obtained results indicate that the tested drugs inhibited proliferation, decreased cell viability, and induced apoptosis in amelanotic melanoma cells. The treatment caused changes in the cell cycle profile and decreased the intracellular level of reduced thiols and mitochondrial membrane potential. The exposure of A375 and C32 cells to minocycline and doxycycline triggered the release of cytochrome c and activated initiator and effector caspases. The anti-melanoma effect of analyzed drugs appeared to be related to the up-regulation of ERK1/2 and MITF. Moreover, it was noticed that minocycline and doxycycline increased the level of LC3A/B, an autophagy marker, in A375 cells. In summary, the study showed the pleiotropic anti-cancer action of minocycline and doxycycline against amelanotic melanoma cells. Considering all results, it could be concluded that doxycycline was a more potent drug than minocycline.

show abstract

Squamous Cell Carcinoma and its Precursors

Gupta,

Dirschka

2024

Rook's Textbook of Dermatology

View full text Add to dashboard Cite

Squamous cell carcinoma (SCC) is the second commonest skin cancer and arises from epidermal keratinocytes or its appendages. The incidence of SCC has increased over the last five decades and is predicted to rise significantly over the next decade. SCC is predominantly a disease of white populations and is especially prevalent in this group in areas of high ambient sun exposure. Predisposing factors include male sex, immune suppression (particularly in those who are organ transplant recipients), sun exposure and advanced age. Precursor lesions such as actinic keratosis and Bowen disease may often be present and patients are more susceptible to developing other UV radiation‐induced skin cancers. SCC has a low rate of metastasis but this increases with SCCs displaying high‐risk features. All SCCs should undergo full clinicopathological correlation and high‐risk SCCs should be managed within a multidisciplinary setting with adequate tumour clearance as the main outcome.

show abstract

The incidence and risk of cutaneous toxicities associated with dabrafenib in melanoma patients: a systematic review and meta-analysis

Cited by 9 publications

References 38 publications

Cancer-Related Alopecia: From Etiologies to Global Management

Cancer-Related Alopecia: From Etiologies to Global Management

The Anticancer Potential of Doxycycline and Minocycline—A Comparative Study on Amelanotic Melanoma Cell Lines

Squamous Cell Carcinoma and its Precursors

Contact Info

Product

Resources

About